Literature DB >> 32365282

Interleukin-22 and intestinal homeostasis: Protective or destructive?

Mojtaba Shohan1,2, Razieh Dehghani3, Ali Khodadadi1, Sajad Dehnavi1,2, Reza Ahmadi4, Nazanin Joudaki1, Sheyda Houshmandfar1, Marziye Shamshiri1, Samira Shojapourian1, Nader Bagheri5.   

Abstract

Interleukin (IL)-22 is a member of IL-10 family cytokines with various immunologic functions. As its name implies, IL-22 is known to be secreted mainly by Th22 cells, a recently discovered lineage of CD4+ T cells. Also, Th17, Th1, natural killer cells, γδT cells, and innate immune cells along with some nonlymphoid cells have been confirmed as secondary cellular sources of IL-22. Different cell types such as bronchial and intestinal epithelial cells, keratinocytes, hepatocytes, dermal fibroblasts, and tubular epithelial cells are affected by IL-22. Both pathologic and protective roles have been attributed to IL-22 in maintaining gut homeostasis and inflammation. According to the latest fast-growing investigations, IL-22 is significantly involved in various pathologies including allergic diseases, infection, autoimmunity, and cancer development. Regulating gut immune responses, barrier integrity, and inflammation is dependent on a diverse complex of cytokines and mediators which are secreted by mucosal immune cells. Several investigations have been designed to recognize the role of IL-22 in gastrointestinal immunity. This article tries to discuss the latest knowledge on this issue and clarify the potential of IL-22 to be used in the future therapeutic approaches of intestinal disorders including inflammatory bowel diseases and colon cancer.
© 2020 International Union of Biochemistry and Molecular Biology.

Entities:  

Keywords:  IL-22; colon cancer; inflammatory bowel diseases; intestinal homeostasis

Year:  2020        PMID: 32365282     DOI: 10.1002/iub.2295

Source DB:  PubMed          Journal:  IUBMB Life        ISSN: 1521-6543            Impact factor:   3.885


  8 in total

1.  Intragastric Administration of Casein Leads to Nigrostriatal Disease Progressed Accompanied with Persistent Nigrostriatal-Intestinal Inflammation Activited and Intestinal Microbiota-Metabolic Disorders Induced in MPTP Mouse Model of Parkinson's Disease.

Authors:  Xinrong Liu; Shuya Liu; Yong Tang; Zhengjia Pu; Hong Xiao; Jieying Gao; Qi Yin; Yan Jia; Qunhua Bai
Journal:  Neurochem Res       Date:  2021-03-15       Impact factor: 3.996

Review 2.  "Sweet death": Fructose as a metabolic toxin that targets the gut-liver axis.

Authors:  Mark A Febbraio; Michael Karin
Journal:  Cell Metab       Date:  2021-10-06       Impact factor: 27.287

Review 3.  Cytokine-Mediated Crosstalk between Immune Cells and Epithelial Cells in the Gut.

Authors:  Mousumi Mahapatro; Lena Erkert; Christoph Becker
Journal:  Cells       Date:  2021-01-09       Impact factor: 6.600

4.  Relationship between mucosal TNF-α expression and Th1, Th17, Th22 and Treg responses in Helicobacter pylori infection.

Authors:  Ghorbanali Rahimian; Milad Shahini Shams Abadi; Yousef Mirzaei; Ali Hussein Mer; Reza Ahmadi; Fatemeh Azadegan-Dehkordi
Journal:  AMB Express       Date:  2022-09-03       Impact factor: 4.126

5.  Amelioration of DSS-Induced Acute Colitis in Mice by Recombinant Monomeric Human Interleukin-22.

Authors:  Suhyun Kim; Eun-Hye Hong; Cheol-Ki Lee; Yiseul Ryu; Hyunjin Jeong; Seungnyeong Heo; Joong-Jae Lee; Hyun-Jeong Ko
Journal:  Immune Netw       Date:  2022-03-30       Impact factor: 5.851

Review 6.  Th17 Cells in Viral Infections-Friend or Foe?

Authors:  Iury Amancio Paiva; Jéssica Badolato-Corrêa; Débora Familiar-Macedo; Luzia Maria de-Oliveira-Pinto
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

7.  "Small" Intestinal Immunopathology Plays a "Big" Role in Lethal Cytokine Release Syndrome, and Its Modulation by Interferon-γ, IL-17A, and a Janus Kinase Inhibitor.

Authors:  Shiv D Kale; Brittney N Mehrkens; Molly M Stegman; Bridget Kastelberg; Henry Carnes; Rachel J McNeill; Amy Rizzo; Saikumar V Karyala; Sheryl Coutermarsh-Ott; Jackie A Fretz; Ying Sun; Jonathan L Koff; Govindarajan Rajagopalan
Journal:  Front Immunol       Date:  2020-06-26       Impact factor: 7.561

Review 8.  Interleukin-22: a potential therapeutic target in atherosclerosis.

Authors:  Jin-Wen Luo; Yuan Hu; Jian Liu; Huan Yang; Peng Huang
Journal:  Mol Med       Date:  2021-08-13       Impact factor: 6.354

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.